Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ACADEMIA
Japan Plans Alvesco Clinical Trial for Coronavirus
Japan’s National Center for Global Health and Medicine (NCGM) is planning a clinical trial for Teijin’s Alvesco (ciclesonide), an inhaled corticosteroid for asthma, for the treatment of pre-symptomatic patients infected with the novel coronavirus. The trial will examine whether Alvesco…
To read the full story
Related Article
- Alvesco Fails in COVID-19 Trial, NCGM Says It Can’t Be Recommended
December 24, 2020
- 26 Patients Enrolled in Alvesco’s Novel Coronavirus Trial: NCGM
June 1, 2020
- Kato Repeats May-End Goal for Avigan OK, Negative for Use in Mildly Ill Patients
May 11, 2020
- Japan Eyes May Approval for Avigan with Investigator-Led Study Data
May 7, 2020
- Japan Can’t Give “Special Approval” for Avigan under Current Law: Abe
April 30, 2020
- Fujifilm Starts Boosting Avigan Production for COVID-19
April 16, 2020
- Fujifilm to Start PII Avigan Trial for COVID-19 in US
April 10, 2020
- Fujifilm Launches Avigan Trial with Completion Eyed in June; Sanofi Too to Test Kevzara in Japan
April 1, 2020
- Fujifilm Wants to Launch Avigan Trial in Japan by End of This Week, Abe Talks to WHO Chief
March 31, 2020
- PM Abe Says Japan to Start Registration Trial for Avigan for COVID-19, Plans Production Boost
March 30, 2020
- Pancreatitis Drug Nafamostat Potentially Effective for COVID-19: Researchers
March 19, 2020
- Japan’s Avigan Stockpile for Some 2 Million People; No Plan for Increase: Govt
March 18, 2020
- Fujifilm Plans Company-Sponsored Avigan Trial for COVID-19 in Japan
March 17, 2020
- Japan Govt Orders 20,000 Alvesco Inhalers as Coronavirus Measure
March 11, 2020
- Camostat Potential Treatment for COVID-19: German Study
March 11, 2020
- Alvesco Inhibits RNA Replications: NIID
March 9, 2020
- With Sudden Spotlight on Alvesco for COVID-19, Teijin Being Flooded with Inquiries
March 6, 2020
- Asthma Drug Alvesco Possibly Effective for COVID-19
March 4, 2020
ACADEMIA
- Cancer Drug Supply Risks Spur Calls for Pricing Reform: JSMO
March 31, 2026
- Japan Ophthalmology Society Flags Off-Label Concerns Ahead of Upneeq Launch
March 30, 2026
- Real-World Study Backs Lecanemab Safety, 90% Stay on Treatment
March 25, 2026
- CAR-T Reimbursement Insufficient, Kyoto University Hospital Chief Warns
March 11, 2026
- Japan Begins Investigator-Led PII of Padcev in Small Bowel Adenocarcinoma
March 3, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…